Eli Lilly And Co LLY will announce its fourth-quarter 2024 monetary outcomes and 2025 monetary steerage on February 6. As per information from Benzinga Professional, the Wall Road estimates gross sales of $13.7 billion, with adjusted EPS of $4.94.
In January, simply earlier than the JP Morgan healthcare convention, Eli Lilly introduced that it expects 2024 full-year worldwide income to be roughly $45.0 billion, representing a 32% development in comparison with the earlier 12 months versus the consensus of $45.50 billion.
The corporate’s anticipated 2024 income is $400 million, or about 3%, under the steerage vary issued through the third-quarter earnings. The steerage contains roughly $3.5 billion for Mounjaro and $1.9 billion for Zepbound.
Additionally Learn: Is Huge Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Analysts are monitoring Eli Lilly’s anticipated improve in gross sales and revenue within the first full quarter, throughout which its weight-loss medicine ceased to be in scarcity.
In October 2024, the FDA decided that Eli Lilly’s tirzepatide injection scarcity had been resolved.
The U.S. pharma large reported third-quarter income of $11.44 billion, up 20% 12 months over 12 months, but it surely missed the consensus of $12.10 billion. Mounjaro gross sales greater than doubled to $3.11 billion from $1.41 billion a 12 months in the past.
Gross sales of Verzenio (a breast most cancers drug) elevated 32% to $1.37 billion, and gross sales of diabetes drug Jardiance fell 2% to $686.4 million.
Zepbound gross sales reached $1.26 billion. Trulicity gross sales fell 22% to $1.30 billion.
Rival Novo Nordisk A/S NVO inventory is buying and selling increased. On Wednesday, the corporate reported gross sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).
GLP-1 diabetes gross sales elevated by 12%, and Weight problems care gross sales elevated by 91%.
Ozempic gross sales elevated 12% to 33.85 billion Danish kroner, and Wegovy gross sales greater than doubled to 19.87 billion Danish kroner.
In keeping with Reuters, traders and analysts anticipate Eli Lilly to stipulate its technique for selling Zepbound this 12 months because it goals to compete with Wegovy, a extra established drug.
Zepbound holds somewhat over 50% of the market, based on IQVIA information cited by an analyst. Eli Lilly started promoting the drug in November.
Worth Motion: LLY inventory is up 2.19% at $843.59 on the final verify on Wednesday.
Learn Subsequent:
Picture by Mohammed_Al_Ali by way of Shutterstock
Overview Ranking:
Speculative
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
